Pinwheel Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pinwheel Therapeutics, Inc. - overview
Location
-, -, US
Primary Industry
Biotechnology
About
Based in the US, Pinwheel Therapeutics is a clinical stage biopharmaceutical company focused on the development of therapeutic assets for emergency anticoagulation management. In February 2026, Pinwheel Therapeutics raised USD 20 million in venture funding from investor 108 BioCapital and Claypond Capital. Pinwheel’s lead asset, Ciraparantag, is a small molecule therapy manufactured using peptide chemistry. It is designed to reverse multiple classes of anticoagulants, including direct oral Factor Xa inhibitors, direct thrombin inhibitors, and both low molecular weight and unfractionated heparins.
The therapy is being developed as a universal reversal option delivered via a ready to use intravenous injection for emergency settings such as trauma, intracranial hemorrhage, and urgent surgery.
Current Investors
Claypond Capital, 108 Biocapital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.